Developed by ![]() ![]() |
Supported by ![]() ![]() |
![]() |
Gilead Sciences Inc. Originator
https://www.gilead.com/
United States Gilead Sciences, Inc. is a multinational biopharmaceutical company that develops and manufactures innovative medicines for life-threatening diseases, including anti-viral therapeutics for HIV/AIDS, Hepatitis B, Hepatitis C and Covid-19. Headquartered in Foster City, California, Gilead was originally founded in 1987 and is currently listed on both the S&P 500 and the NASDAQ Biotechnology Index. |
Lenacapavir Compound Structure
Sourced From DrugBank
Aqueous Solution, Oral solid form
Oral, Subcutaneous, Intramuscular, To be determined
Not provided
LEN oral tablets 300 mg; each injection contains 927 mg of lenacapavir in solution. Dose for investigational Once-Yearly formulation is 5000 mg.
Oral tablets 300 mg taken daily or weekly; Six-monthly injectable; Once-yearly investigational injectable.
5000 mg
For PrEP: Initiation Option 1: Day 1: 927 mg by subcutaneous injection and 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally (2 x 300-mg tablets). Initiation Option 2: Day 1: 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally (2 x 300-mg tablets). Day 8: 300 mg orally (1 x 300-mg tablet). Day 15: 927 mg by subcutaneous injection. Maintenance: 927 mg by subcutaneous injection every 26 weeks +/- 2 weeks from date of last injection. For the treatment indication, lenacapavir is administered as part of a full treatment regimen with the relevant associated medicines.
Not provided
Not provided
No delivery device
Compound is commercially manufactured.
Equipment for injectable: Stainless steel pharmaceutical reactors, glass-lined reactors, rotary evaporator (rotovap), flash chromatography columns, stainless steel autoclave, cooling bath, silica gel chromatography columns, vacuum distillation apparatus, simulated moving bed chromatography system, Chiralpak columns.
Storage of injectable lenacapavir in borosilicate vials is contraindicated due to issues with chemical compatibility. Instead, it is recommended that vials are made from aluminosilicate glass.
Proton nuclear magnetic resonance (1H NMR), High-performance liquid chromatography (HPLC), Ultra-Performance Liquid Chromatography (UPLC).
NCT04150068
https://clinicaltrials.gov/ct2/show/NCT04150068
Phase II/III
Active, not recruiting
Gilead Sciences
Not provided
Evaluate the antiviral activity of Lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV with multi-drug resistance.
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2019-11-21 00:00:00
Anticipated Date of Last Follow-up
2024-06-26 00:00:00
Estimated Primary Completion Date
Not provided
Estimated Completion Date
2027-01-01 00:00:00
Actual Primary Completion Date
2020-10-05 00:00:00
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Adult aged ≥ 18 years (at all sites) or adolescent aged ≥ 12 and weighing ≥ 35 kg (at sites in North America and Dominican Republic). Currently receiving a stable failing ARV regimen for > 8 weeks. Have HIV-1 RNA ≥ 400 copies/mL at screening. Have multidrug resistance (resistance to ≥2 agents from ≥3 of the 4 main classes of ARV). Have no more than 2 fully active ARV remaining from the 4 main classes that can be effectively combined to form a viable regimen. Able and willing to receive an Optimized Background Regimen (OBR) together with Lenacapavir.
Interventional (clinical trial)
72
Randomized
Sequential assignment
Not provided
Quadruple-blind masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Treatment
Type of key results | Title | Website link |
---|---|---|
Article | Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection | https://www.nejm.org/doi/10.1056/NEJMoa2115542 |
NCT04143594
https://clinicaltrials.gov/ct2/show/NCT04143594
Phase II
Completed
Gilead Sciences
Not provided
Evaluate the efficacy of Lenacapavir containing regimens in people living with HIV
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2019-11-22 00:00:00
Anticipated Date of Last Follow-up
2023-10-03 00:00:00
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2021-09-30 00:00:00
Actual Completion Date
2023-09-13 00:00:00
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Antiretroviral (ARV) naïve with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any duration), or HIV-1 treatment (< 10 days therapy total) > 1 month prior to screening is permitted. HIV-1 RNA ≥ 200 copies/mL at screening. CD4+ cell count ≥ 200 cells/microliter at screening.
Interventional (clinical trial)
183
Randomized
Parallel Assignment
Not provided
Open label
None (Open Label)
Treatment
Type of key results | Title | Website link |
---|---|---|
Abstract | CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study | https://i-base.info/htb/42313 |
Article | Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial | https://doi.org/10.1016/S2352-3018(22)00291-0 |
Article | Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks | https://doi.org/10.1093%2Fofid%2Fofab466.073 |
NCT04811040
https://clinicaltrials.gov/ct2/show/NCT04811040
Phase I
Completed
Gilead Sciences
Not provided
Evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and GS-2872 in combination with the HIV capsid inhibitor lenacapavir
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2021-04-08 00:00:00
Anticipated Date of Last Follow-up
2023-10-26 00:00:00
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2023-04-18 00:00:00
Actual Completion Date
2023-10-17 00:00:00
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
On first-line antiretroviral therapy (ART) for ≥ 2 years prior to screening. A change in ART regimen ≥ 28 days prior to screening for reasons other than virologic failure (VF) (eg, tolerability, simplification, drug-drug interaction profile) is allowed.
Interventional (clinical trial)
32
Randomized
Parallel Assignment
Not provided
Double-blind masking
Double (Participant, Investigator). Clinical pharmacologist and sponsor are not masked to treatment assignment.
Treatment
NCT03739866
https://clinicaltrials.gov/ct2/show/NCT03739866
Phase I
Completed
Gilead Sciences
Not provided
Separately evaluate the short-term antiviral activity of both lenacapavir and tenofovir alafenamide with respect to plasma HIV-1 RNA reduction in antiretroviral or capsid inhibitor naïve patients
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2018-11-26 00:00:00
Anticipated Date of Last Follow-up
2021-03-16 00:00:00
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2019-11-14 00:00:00
Actual Completion Date
2020-06-15 00:00:00
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
No
Treatment naïve or experienced but CAI and integrase strand transfer inhibitor (INSTI) naïve, and have not received any antiretroviral therapy (ART) within 12 weeks of screening.
Interventional (clinical trial)
53
Randomized
Parallel Assignment
Not provided
Double-blind masking
Double (Participant, Investigator)
Treatment
Type of key results | Title | Website link |
---|---|---|
Article | Clinical targeting of HIV capsid protein with a long-acting small molecule | https://doi.org/10.1038/s41586-020-2443-1 |
NCT05729568
https://clinicaltrials.gov/study/NCT05729568
Phase II
Active, not recruiting
Gilead Sciences
Not provided
Evaluate the Safety and Efficacy of bNAbs GS-5423 and GS-2872 in Combination With Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection.
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-05-15 00:00:00
Anticipated Date of Last Follow-up
2024-07-12 00:00:00
Estimated Primary Completion Date
2025-03-01 00:00:00
Estimated Completion Date
2029-12-01 00:00:00
Actual Primary Completion Date
2024-07-02 00:00:00
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Participants are required to be receiving a stable ART regimen with no clinically significant documented resistance (except isolated NRTI mutations). Plasma HIV-1 RNA < 50 copies/mL at screening visit 2 and documented plasma HIV-1 RNA < 50 copies/mL for ≥ 12 months preceding screening visit 2.
Interventional (clinical trial)
83
Randomized
Parallel Assignment
Not provided
Open label
None (Open Label)
Treatment
NCT06289361
https://clinicaltrials.gov/study/NCT06289361
Marketed
Not yet recruiting
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Immunovirological follow-up and safety of HIV-infected patients receiving lenacapavir under compassionate access in France between 01/01/2021 and 12/31/2023
Cohort IMEA 070 -Lenacapavir Compassional
Not provided
Not provided
Anticipated Start Date
2024-04-01 00:00:00
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
2024-03-20 00:00:00
Estimated Primary Completion Date
2024-04-15 00:00:00
Estimated Completion Date
2024-07-30 00:00:00
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Not provided
Observational studies (incl. patient registries)
58
Not provided
Not provided
Not provided
Not provided
Not provided
Treatment
Not provided
https://doi.org/10.1016/S0140-6736(25)00405-2
Phase I
Not provided
Gilead Sciences Inc.
Not provided
Not provided
Intervention 1
Intervention 2
Not provided
Not provided
Anticipated Start Date
Not provided
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
Not provided
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Not provided
Not provided
Interventional (clinical trial)
40
Not provided
Parallel Assignment
Not provided
Not provided
Not provided
PrEP
Type of key results | Title | Website link |
---|---|---|
Article | Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study | https://doi.org/10.1016/S0140-6736(25)00405-2 |
NCT04994509
https://clinicaltrials.gov/study/NCT04994509
Phase III
Active, not recruiting
Gilead Sciences
The goal of this study is to evaluate the efficacy in preventing HIV infection of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF), in adolescent girls and young women.
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2021-08-30 00:00:00
Anticipated Date of Last Follow-up
2024-02-26 00:00:00
Estimated Primary Completion Date
2024-09-01 00:00:00
Estimated Completion Date
2027-07-01 00:00:00
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Yes
Accepts lactating individuals
Yes
Accepts healthy individuals
Yes
Key Inclusion Criteria: * Incidence Phase * HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months. * Sexually active (has had \> 1 vaginal intercourse within the last 3 months) with cisgender male individuals (CGM). * Randomized Phase * Negative fourth generation HIV-1 antibody (Ab)/antigen (Ag) test confirmed with central HIV-1 testing. * Estimated glomerular filtration rate (GFR) ≥ 60 mL/min at screening. * Body weight ≥ 35 kg. Key Exclusion Criteria: * Prior receipt of an HIV vaccine. * Prior use of long-acting systemic HIV pre-exposure prophylaxis (PrEP) or or HIV PEP (postexposure prophylaxis). Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Interventional (clinical trial)
5368
Randomized
Parallel Assignment
Not provided
Double-blind masking
Double (Participant, Investigator)
PrEP
NCT04925752
https://clinicaltrials.gov/study/NCT04925752
Phase III
Active, not recruiting
Gilead Sciences
The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2021-06-28 00:00:00
Anticipated Date of Last Follow-up
2024-07-11 00:00:00
Estimated Primary Completion Date
2024-12-01 00:00:00
Estimated Completion Date
2028-05-01 00:00:00
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Key Inclusion Criteria: Incidence Phase * CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection. * HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months. * Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following: * Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks. * History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks. * Self-reported use of stimulants with sex in the last 12 weeks. Randomized Phase * Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification
Interventional (clinical trial)
3295
Randomized
Parallel Assignment
Not provided
Double-blind masking
Double (Participant, Investigator)
PrEP
NCT06101329
https://clinicaltrials.gov/study/NCT06101329
Phase II
Recruiting
Gilead Sciences
Not provided
Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States.
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-11-17 00:00:00
Anticipated Date of Last Follow-up
2024-08-12 00:00:00
Estimated Primary Completion Date
2028-01-01 00:00:00
Estimated Completion Date
2028-01-01 00:00:00
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
Cisgender women aged 18 and older who report at least one episode of condomless vaginal or anal sex with a cisgender man in the twelve months prior to enrollment.
Interventional (clinical trial)
250
Randomized
Parallel Assignment
Not provided
Open label
None (Open Label)
PrEP
NCT06101342
https://clinicaltrials.gov/study/NCT06101342
Phase II
Recruiting
Gilead Sciences
PWUD (People Who Use Drugs).
Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs.
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-12-13 00:00:00
Anticipated Date of Last Follow-up
2024-08-08 00:00:00
Estimated Primary Completion Date
2027-07-01 00:00:00
Estimated Completion Date
2027-07-01 00:00:00
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Participant inclusion criteria requires a positive urine drug screen for any drug of misuse including (but not limited to) opioids (eg, fentanyl, heroin), stimulants (eg, cocaine, amphetamines), psychoactive drugs (eg, benzodiazepines), or a combination of these drugs. Participants must also display evidence of recent injection(s) (eg, track marks) and self-report of injection paraphernalia sharing within the last 30 days.
Interventional (clinical trial)
250
Randomized
Parallel Assignment
Not provided
Open label
None (Open Label)
PrEP
NCT06513312
https://clinicaltrials.gov/study/NCT06513312
Phase II
Not yet recruiting
Gilead Sciences
The goals of this clinical study are to learn more about the study drug lenacapavir (LEN), by comparing the consistent and continuous use of LEN and emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada®) (F/TDF), then by observing the safety of LEN and F/TDF, evaluating the acceptability of LEN injections and oral F/TDF, and observe how LEN moves throughout the body in people who would benefit from pre-exposure prophylaxis (PrEP). The primary objective of this study is to compare LEN and F/TDF consistent and continuous use among people who would benefit from PrEP.
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
2024-09-01 00:00:00
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
2024-08-22 00:00:00
Estimated Primary Completion Date
2027-01-01 00:00:00
Estimated Completion Date
2029-07-01 00:00:00
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Key Inclusion Criteria: - Able to comprehend and provide a signed written informed consent, which must be obtained prior to initiation of study procedures. - Cisgender men who have sex with men, transgender women, transgender men, cisgender women, and nonbinary people - Increased likelihood of HIV acquisition as indicated by at least one of the following: - Condomless sex with ≥ 2 partners in the past 6 months - Diagnosis of a bacterial sexually transmitted infection (STI) in the past 12 months - Engagement in sex work or transactional sex in the past 12 months - Use of ≥ 2 courses of nonoccupational HIV post-exposure prophylaxis (nPEP) in the past 12 months - Condomless sex with a partner living with HIV who has unknown or unsuppressed viral load (≥ 200 copies/mL) in the past 12 months
Interventional (clinical trial)
262
Randomized
Parallel Assignment
Not provided
Open label
None (Open Label)
PrEP
No proprietary excipient used
No novel excipient or existing excipient used
No residual solvent used
There are either no relevant patents or these were not yet submitted to LAPaL
Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W, Begley R, Chiu A, Mulato A, Hansen D, Singer E, Tsai LK, Bam RA, Chou CH, Canales E, Brizgys G, Zhang JR, Li J, Graupe M, Morganelli P, Liu Q, Wu Q, Halcomb RL, Saito RD, Schroeder SD, Lazerwith SE, Bondy S, Jin D, Hung M, Novikov N, Liu X, Villasenor AG, Cannizzaro CE, Hu EY, Anderson RL, Appleby TC, Lu B, Mwangi J, Liclican A, Niedziela-Majka A, Papalia GA, Wong MH, Leavitt SA, Xu Y, Koditek D, Stepan GJ, Yu H, Pagratis N, Clancy S, Ahmadyar S, Cai TZ, Sellers S, Wolckenhauer SA, Ling J, Callebaut C, Margot N, Ram RR, Liu YP, Hyland R, Sinclair GI, Ruane PJ, Crofoot GE, McDonald CK, Brainard DM, Lad L, Swaminathan S, Sundquist WI, Sakowicz R, Chester AE, Lee WE, Daar ES, Yant SR, Cihlar T: Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020 Aug;584(7822):614-618. doi: https://doi.org/10.1038/s41586-020-2443-1. Epub 2020 Jul 1.
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis1-5. However, some people living with HIV who are heavily treatment-experienced have limited or no treatment options, owing to multidrug resistance6. In addition, suboptimal adherence to oral daily regimens can negatively affect the outcome of treatment-which contributes to virologic failure, resistance generation and viral transmission-as well as of pre-exposure prophylaxis, leading to new infections1,2,4,7-9. Long-acting agents from new antiretroviral classes can provide much-needed treatment options for people living with HIV who are heavily treatment-experienced, and additionally can improve adherence10. Here we describe GS-6207, a small molecule that disrupts the functions of HIV capsid protein and is amenable to long-acting therapy owing to its high potency, low in vivo systemic clearance and slow release kinetics from the subcutaneous injection site. Drawing on X-ray crystallographic information, we designed GS-6207 to bind tightly at a conserved interface between capsid protein monomers, where it interferes with capsid-protein-mediated interactions between proteins that are essential for multiple phases of the viral replication cycle. GS-6207 exhibits antiviral activity at picomolar concentrations against all subtypes of HIV-1 that we tested, and shows high synergy and no cross-resistance with approved antiretroviral drugs. In phase-1 clinical studies, monotherapy with a single subcutaneous dose of GS-6207 (450 mg) resulted in a mean log10-transformed reduction of plasma viral load of 2.2 after 9 days, and showed sustained plasma exposure at antivirally active concentrations for more than 6 months. These results provide clinical validation for therapies that target the functions of HIV capsid protein, and demonstrate the potential of GS-6207 as a long-acting agent to treat or prevent infection with HIV.
Bester SM, Wei G, Zhao H, Adu-Ampratwum D, Iqbal N, Courouble VV, Francis AC, Annamalai AS, Singh PK, Shkriabai N, Van Blerkom P, Morrison J, Poeschla EM, Engelman AN, Melikyan GB, Griffin PR, Fuchs JR, Asturias FJ, Kvaratskhelia M: Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science. 2020 Oct 16;370(6514):360-364. doi: https://doi.org/10.1126/science.abb4808
The potent HIV-1 capsid inhibitor GS-6207 is an investigational principal component of long-acting antiretroviral therapy. We found that GS-6207 inhibits HIV-1 by stabilizing and thereby preventing functional disassembly of the capsid shell in infected cells. X-ray crystallography, cryo-electron microscopy, and hydrogen-deuterium exchange experiments revealed that GS-6207 tightly binds two adjoining capsid subunits and promotes distal intra- and inter-hexamer interactions that stabilize the curved capsid lattice. In addition, GS-6207 interferes with capsid binding to the cellular HIV-1 cofactors Nup153 and CPSF6 that mediate viral nuclear import and direct integration into gene-rich regions of chromatin. These findings elucidate structural insights into the multimodal, potent antiviral activity of GS-6207 and provide a means for rationally developing second-generation therapies.
No documents were uploaded
|
Collaborate for developmentConsider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology Not provided |
|
Share technical information for match-making assessmentProvide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit Not provided |
|
Work with MPP to expand access in LMICsIn the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing Not provided |
Not provided